Literature DB >> 29133367

Regulatory T-cell Genes Drive Altered Immune Microenvironment in Adult Solid Cancers and Allow for Immune Contextual Patient Subtyping.

Jurriaan Brouwer-Visser1, Wei-Yi Cheng2, Anna Bauer-Mehren3, Daniela Maisel3, Katharina Lechner3, Emilia Andersson3, Joel T Dudley4, Francesca Milletti2.   

Abstract

Background: The tumor microenvironment is an important factor in cancer immunotherapy response. To further understand how a tumor affects the local immune system, we analyzed immune gene expression differences between matching normal and tumor tissue.
Methods: We analyzed public and new gene expression data from solid cancers and isolated immune cell populations. We also determined the correlation between CD8, FoxP3 IHC, and our gene signatures.
Results: We observed that regulatory T cells (Tregs) were one of the main drivers of immune gene expression differences between normal and tumor tissue. A tumor-specific CD8 signature was slightly lower in tumor tissue compared with normal of most (12 of 16) cancers, whereas a Treg signature was higher in tumor tissue of all cancers except liver. Clustering by Treg signature found two groups in colorectal cancer datasets. The high Treg cluster had more samples that were consensus molecular subtype 1/4, right-sided, and microsatellite-instable, compared with the low Treg cluster. Finally, we found that the correlation between signature and IHC was low in our small dataset, but samples in the high Treg cluster had significantly more CD8+ and FoxP3+ cells compared with the low Treg cluster.Conclusions: Treg gene expression is highly indicative of the overall tumor immune environment.Impact: In comparison with the consensus molecular subtype and microsatellite status, the Treg signature identifies more colorectal tumors with high immune activation that may benefit from cancer immunotherapy. Cancer Epidemiol Biomarkers Prev; 27(1); 103-12. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29133367     DOI: 10.1158/1055-9965.EPI-17-0461

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  10 in total

1.  Identification of potential biomarkers and pivotal biological pathways for prostate cancer using bioinformatics analysis methods.

Authors:  Zihao He; Xiaolu Duan; Guohua Zeng
Journal:  PeerJ       Date:  2019-10-04       Impact factor: 2.984

2.  Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.

Authors:  Paola Cruz-Tapias; Vlada Zakharova; Oscar M Perez-Fernandez; William Mantilla; Sandra RamÍRez-Clavijo; Slimane Ait-Si-Ali
Journal:  Cancers (Basel)       Date:  2019-08-08       Impact factor: 6.639

3.  Identification of potential diagnostic and prognostic biomarkers for prostate cancer.

Authors:  Qiang Zhang; Xiujuan Yin; Zhiwei Pan; Yingying Cao; Shaojie Han; Guojun Gao; Zhiqin Gao; Zhifang Pan; Weiguo Feng
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

4.  Identification of differentially expressed genes in non-small cell lung cancer.

Authors:  Ke Wang; Ruo Chen; Zhuan Feng; Yu-Meng Zhu; Xiu-Xuan Sun; Wan Huang; Zhi-Nan Chen
Journal:  Aging (Albany NY)       Date:  2019-12-09       Impact factor: 5.682

5.  Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance.

Authors:  An Zhi Zhang; Xin Yuan; Wei Hua Liang; Hai Jun Zhang; Ya Li; Yu Fang Xie; Jiang Fen Li; Chen Hao Jiang; Fan Ping Li; Xi Hua Shen; Li Juan Pang; Hong Zou; Wen Hu Zhou; Feng Li; Jian Ming Hu
Journal:  Front Cell Dev Biol       Date:  2022-02-17

6.  Downregulation of B3GNT6 is a predictor of poor outcomes in patients with colorectal cancer.

Authors:  Shihan Xiao; Chen Yang; Yang Zhang; Chen Lai
Journal:  World J Surg Oncol       Date:  2022-04-07       Impact factor: 3.253

7.  T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis.

Authors:  Laura Brennan; Jurriaan Brouwer-Visser; Eveline Nüesch; Maria Karpova; Astrid Heller; Fabien Gaire; Meike Schneider; Bruno Gomes; Konstanty Korski
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

8.  PRIM2 Promotes Cell Cycle and Tumor Progression in p53-Mutant Lung Cancer.

Authors:  Taoyuan Wang; Tiansheng Tang; Youguo Jiang; Tao He; Luyu Qi; Hongkai Chang; Yaya Qiao; Mingming Sun; Changliang Shan; Xinyuan Zhu; Jianshi Liu; Jiyan Wang
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

9.  Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

Authors:  Alan Mackay; Anna Burford; Valeria Molinari; David T W Jones; Elisa Izquierdo; Jurriaan Brouwer-Visser; Felice Giangaspero; Christine Haberler; Torsten Pietsch; Thomas S Jacques; Dominique Figarella-Branger; Daniel Rodriguez; Paul S Morgan; Pichai Raman; Angela J Waanders; Adam C Resnick; Maura Massimino; Maria Luisa Garrè; Helen Smith; David Capper; Stefan M Pfister; Thomas Würdinger; Rachel Tam; Josep Garcia; Meghna Das Thakur; Gilles Vassal; Jacques Grill; Tim Jaspan; Pascale Varlet; Chris Jones
Journal:  Cancer Cell       Date:  2018-05-14       Impact factor: 31.743

10.  An In Vivo Inflammatory Loop Potentiates KRAS Blockade.

Authors:  Kristina A M Arendt; Giannoula Ntaliarda; Vasileios Armenis; Danai Kati; Christin Henning; Georgia A Giotopoulou; Mario A A Pepe; Laura V Klotz; Anne-Sophie Lamort; Rudolf A Hatz; Sebastian Kobold; Andrea C Schamberger; Georgios T Stathopoulos
Journal:  Biomedicines       Date:  2022-03-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.